Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Vaxcyte Inc

Healthcare US PCVX

48.02USD
1.09(2.32%)

Last update at 2026-06-04T17:50:00Z

Day Range

47.4248.50
LowHigh

52 Week Range

44.2082.04
LowHigh

Fundamentals

  • Previous Close 46.93
  • Market Cap7474.22M
  • Volume493088
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-507.87802M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -22.99500M
  • Diluted EPS TTM-4.29

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -223.48500M -100.07700M -89.21700M -50.27400M -29.48500M
Minority interest - - - - -
Net income -239.64000M -100.08400M -87.81900M -53.49900M -29.48500M
Selling general administrative 39.81M 25.26M 16.02M 8.55M 5.39M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 9.20M 3.46M 1.41M 1.23M 1.04M
Ebit -232.25600M -103.67000M -89.58100M -54.15300M -29.45200M
Ebitda -189.77800M -98.28400M -86.85900M -48.86700M -28.41500M
Depreciation and amortization 42.48M 5.39M 2.72M 5.29M 1.04M
Non operating income net other - 3.59M 0.36M - -
Operating income -232.25600M -103.67000M -89.58100M -54.15300M -35.53300M
Other operating expenses 207.33M 102.08M 87.10M 53.92M 35.53M
Interest expense 0.00200M 0.00700M 0.00700M 0.04M 0.07M
Tax provision - - - - -
Interest income 8.36M 0.34M 0.24M 0.63M 0.90M
Net interest income 8.35M 0.34M 0.24M 0.59M 0.83M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 16.16M 0.00700M -1.39800M 3.23M 6.12M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 207.33M 102.08M 87.10M 53.92M 35.53M
Cost of revenue - - - - -
Total other income expense net 8.77M 3.59M 0.36M 3.88M 5.22M
Discontinued operations - - - - -
Net income from continuing ops -223.48500M -100.07700M -89.21700M -50.27400M -29.48500M
Net income applicable to common shares -223.48500M -100.07700M -89.21700M -50.27400M -29.48500M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1407.92M 1006.18M 324.34M 392.83M 65.70M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 12.12M 11.18M 10.38M 2.80M 2.75M
Total liab 167.45M 52.56M 40.32M 46.98M 172.07M
Total stockholder equity 1240.47M 953.61M 284.02M 345.84M -106.37300M
Deferred long term liab - 0.50M 0.50M 0.10M -
Other current liab 123.64M 24.82M 16.68M 17.08M 7.51M
Common stock 0.10M 0.08M 0.06M 0.05M 0.00700M
Capital stock 0.10M 0.08M 0.06M 0.05M 0.00700M
Retained earnings -924.39200M -522.12600M -298.64100M -198.56400M -109.34700M
Other liab - 0.00900M 0.10M 0.12M 0.26M
Good will - - - - -
Other assets 0.00000M 5.43M 4.96M 0.55M 0.58M
Cash 397.45M 834.66M 68.98M 386.20M 58.98M
Cash and equivalents - - - - -
Total current liabilities 145.34M 40.52M 28.72M 46.86M 11.05M
Current deferred revenue - - - - -
Net debt -368.22700M -816.71600M -52.20200M -386.20000M -58.81500M
Short term debt 7.11M 5.91M 5.28M - 0.16M
Short long term debt - - - - -
Short long term debt total 29.22M 17.94M 16.78M - 0.16M
Other stockholder equity 2164.58M 1476.02M 258.51M 544.35M 2.97M
Property plant equipment - 31.65M 35.91M 3.27M 3.39M
Total current assets 1095.95M 942.55M 256.35M 389.00M 61.72M
Long term investments 162.68M 26.55M 27.12M - -
Net tangible assets - 953.61M 284.02M 345.84M -106.37300M
Short term investments 682.78M 96.72M 176.99M - -
Net receivables 3.61M 1.00M 1.20M 0.30M 0.20M
Long term debt - - - - 0.45M
Inventory - - - - -
Accounts payable 14.59M 9.79M 6.76M 29.79M 3.38M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.18M -0.36100M -0.24100M -392.82600M -2.98200M
Additional paid in capital - - - - -
Common stock total equity - - 0.06M 0.05M 0.00700M
Preferred stock total equity - - - - -
Retained earnings total equity - - -298.64100M -198.56400M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 37.56M 5.43M 4.96M 0.55M 0.58M
Deferred long term asset charges - - - - -
Non current assets total 311.96M 63.62M 67.99M 3.82M 3.98M
Capital lease obligations 29.22M 17.94M 16.78M 0.00000M 0.16M
Long term debt total - - - - 0.45M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 74.58M -212.30800M -1.10500M -1.19500M -1.77300M
Change to liabilities 2.90M -12.47000M 26.10M 0.87M 1.27M
Total cashflows from investing activities 74.58M -212.30800M -1.10500M -1.19500M -1.77300M
Net borrowings - - -0.06100M -0.27800M -0.28300M
Total cash from financing activities 861.55M 17.80M 374.87M 41.57M 62.19M
Change to operating activities 9.84M -24.53500M 9.17M 3.04M 0.63M
Net income -223.48500M -100.07700M -89.21700M -50.27400M -29.48500M
Change in cash 765.67M -316.34400M 327.22M -7.11400M 29.95M
Begin period cash flow 69.86M 386.20M 58.98M 66.09M 36.14M
End period cash flow 835.53M 69.86M 386.20M 58.98M 66.09M
Total cash from operating activities -170.59700M -121.39300M -46.62800M -47.14500M -30.46600M
Issuance of capital stock 856.48M 13.90M 377.25M 42.50M 62.34M
Depreciation 9.20M 3.46M 1.41M 1.23M 1.04M
Other cashflows from investing activities - 0.03M 0.05M - 0.00100M
Dividends paid - - -0.37400M - -
Change to inventory - - - 2.87M -1.18700M
Change to account receivables - - - 0.87M 1.27M
Sale purchase of stock 1.03M 0.89M 0.37M 42.94M 62.47M
Other cashflows from financing activities 4.03M 3.01M 107.56M 41.84M 62.47M
Change to netincome 30.95M 12.23M 5.91M -2.01100M -3.91300M
Capital expenditures 5.85M 6.55M 1.16M 1.20M 1.77M
Change receivables - - - - -
Cash flows other operating - -30.67900M 7.09M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - -315.90500M 327.14M - -
Change in working capital 12.74M -37.00500M 35.27M 3.91M 1.90M
Stock based compensation 23.65M 10.73M 5.43M 1.19M 0.75M
Other non cash items 7.30M 1.50M 0.18M -3.19700M -4.71300M
Free cash flow -176.44500M -127.94800M -47.78300M -48.34000M -32.24000M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
PCVX
Vaxcyte Inc		 1.09 2.32% 48.02 - - - 5.41 -14.4283
NVO
Novo Nordisk A/S		 1.81 4.32% 43.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Vaxcyte Inc

825 Industrial Road, San Carlos, CA, United States, 94070

Key Executives

Name Title Year Born
Mr. Grant E. Pickering M.B.A. Co-Founder, CEO & Director 1968
Mr. Andrew L. Guggenhime M.B.A. Pres, CFO & Principal Accounting Officer 1968
Mr. James Wassil M.B.A., M.S. Exec. VP & COO 1969
Mr. Paul W. Sauer M.B.A., MBA Sr. VP of Process Devel. & Manufacturing 1961
Mr. Harp Dhaliwal M.B.A. Sr. VP of Commercial Manufacturing & Supply Chain 1973
Dr. Ashish Khanna M.B.A., Ph.D. Co-Founder and Chief Bus. Officer 1972
Dr. Jeff Fairman Ph.D. Co-Founder & VP of Research 1964
Ms. Janet Graesser VP of Corp. Communications & Investor Relations NA
Mr. Mikhail Eydelman J.D. Sr. VP, Gen. Counsel & Corp. Sec. 1978
Karen Alderete Exec. Director of HR NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.